Amedisys Inc (AMED): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report


Amedisys reported a decent third-quarter 2014 with adjusted earnings from continuing operations of $0.28 per share, ahead of the Zacks Consensus Estimate by an impressive 64.7%. It also marked a massive improvement compared to the year-ago loss of a penny. Although, revenues of $305 million were down 0.3%, the top line remained at par with the estimate. Owing to the company's successful initiative of reducing cost per visit, the Home Health segment showed a strong performance. The company is also working hard to revive the Hospice platform through better cost management which should improve its organic growth in this segment. Amedisys is poised to gain from a solid foothold in the still untapped home health and Hospice services market. In addition, positive demographic trend is another upside. Thus, we upgrade the stock to Outperform.


Amedisys Inc. (AMED) provides home health and hospice services throughout the U.S. to a 360,000 and growing chronic, co-morbid, and aging American population. The company also offers clinically focused programs for chronic conditions and various diseases such as diabetes, coronary artery disease, congestive heart failure, orthopedics, complex wound care, geriatric surgical recovery, balance retraining, behavioral health and stroke recovery, as well as various rehabilitative programs. It provides hospice services to patients using an interdisciplinary care team comprising a physician, nurses, home health aides, social workers, therapists, dieticians, volunteers, counselors, chaplains and bereavement coordinators, when required. Amedisys was founded in 1982 and is headquartered in Baton Rouge, LA.

As of Sep 31, 2014, the company had 316 Medicare-certified home health care centers, 80 Medicare-certified hospice care centers in 34 states within the U.S., the District of Columbia and Puerto Rico.

The company depends on reimbursement from Medicare (for chronic care) for a significant portion of its revenue due to the age demographics of its patient base (average age of 81). Medicare represented approximately 84% of Amedisys' net service revenue in 2013 compared with 82% in 2012.

Amedisys plans to diversify its payment sources and becomes less reliant upon Medicare, based on the needs of the aging population, uncertainty surrounding health care reform, and new health care models currently in development, such as Accountable Care Organizations (ACOs).

Health Care Reform Update

In Nov 2012, Centers for Medicare and Medicaid Services (CMS) issued a final rule to update and revise Medicare home health reimbursement rates for fiscal 2013. The final rule includes a 2.3% market basket increase, a 1% reduction mandated by the Patient Protection and Affordable Care Act (PPACA), and a negative 1.32% case-mix adjustment. The net effect of these changes is a 0.04% decrease in the base rate. Additionally, the wage index was updated which impacts providers differently depending on their geographic location and a change made to the outlying observation eligibility standards. In total, CMS estimates that the effect of these changes will result in a 0.01% reduction in reimbursement to home health providers.

In Jul 2012, CMS issued a notice to update and revise the Medicare hospice wage index for fiscal 2013. The notice includes a 2.6% market basket update, which is reduced by a productivity adjustment of 0.7%, a 0.3% adjustment from the PPACA and 0.7% for the updated wage index and budget neutrality adjustment factor. The net effect of the notice increases the base rate for 2013 by 0.9%.

In Mar 2010, President Obama introduced the Patient Protection and Affordable Care Act (PPACA) and the Health Care and Education Reconciliation Act of 2010 (HCERA), which amends the PPACA (collectively, the Health Care Reform Bills). The Health Care Reform Bills made a number of changes to Medicare payment rates, including the reinstatement of the 3% home health rural add-on, which began on Apr 1, 2010 (expiring Jan 1, 2016). The Health Care Reform Bills also include a systemic rebasing of the amount that the CMS reimburses for home health services, to be phased in over four years, beginning in 2014.

Amedisys Inc (AMED): Read the Full Research Report
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AMEDISYS INC (AMED): Free Stock Analysis Report

To read this article on click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

This article appears in: Investing , Stocks

Referenced Stocks: AMED , CMS

More from

Related Videos



Most Active by Volume

  • $16.75 ▲ 0.12%
  • $132.54 ▲ 0.88%
  • $3.01 ▲ 19.92%
  • $34.76 ▲ 2.75%
  • $9.15 ▼ 3.58%
  • $34.71 ▼ 1.03%
  • $46.90 ▼ 1.10%
  • $15.27 ▼ 1.55%
As of 5/22/2015, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by